- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic myeloid leukaemia
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 820KB)
- Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 201KB)
Asciminib – November 2022
Asciminib: Tablet 20 mg, Tablet 40 mg; Scemblix®
Last updated
3 March 2023